Body

Coaxing iPS cells to become more specialized prior to transplantation cuts rejection risk

STANFORD, Calif. — For many scientists, the clinical promise of stem cells has been dampened by very real concerns that the immune system will reject the transplanted cells before they could render any long-term benefit. Previous research in mice has suggested that even stem cells produced from the subject's own tissue, called iPS cells, can trigger an immune attack.

Phase I study of DMOT4039A in patients with pancreatic or ovarian cancer

A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.

Genetic profile predicts which bladder cancer patients will benefit from early chemotherapy

CHICAGO, IL (May 30, 2014)—Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.

For the first time in the lab, researchers see stem cells take key step toward development

CHAMPAIGN, Ill. — The gap between stem cell research and regenerative medicine just became a lot narrower, thanks to a new technique that coaxes stem cells, with potential to become any tissue type, to take the first step to specialization. It is the first time this critical step has been demonstrated in a laboratory.

University of Illinois researchers, in collaboration with scientists at Notre Dame University and the Huazhong University of Science and Technology in China, published their results in the journal Nature Communications.

Trial uncovers potential dangers of chemotherapy regimen for bladder cancer patients

CHICAGO, IL (May 30, 2014)—Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers at Fox Chase Cancer Center was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs.

Atomic structure of essential circadian clock protein complex determined

Structural biologists have made important progress towards better understanding the functioning of the circadian clock. The circadian or inner clock coordinates the sleep-wake rhythm and many other body processes that regulate, for example, metabolism, blood pressure, and the immune system.

More patients with ovarian cancer are receiving chemotherapy before surgery

CHICAGO, IL (May 30, 2014)—The use of chemotherapy before surgery to remove ovarian cancer has increased dramatically in recent decades, particularly among certain patients, according to a new analysis from Fox Chase Cancer Center that will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology.

Compounds in saliva and common body proteins may fend off DNA-damaging chemicals

A compound in saliva, along with common proteins in blood and muscle, may protect human cells from powerful toxins in tea, coffee and liquid smoke flavoring, according to results of a new study led by investigators at the Johns Hopkins Kimmel Cancer Center.

Standard approaches to menopause symptoms discount non-Western experiences

Dr Mwenza T. Blell of the University of Bristol interviewed 257 British Pakistani women aged 39-61 living in West Yorkshire and found that the standard checklist approach to studying menopause symptoms, which ignores women's understanding of their own experience, leaves researchers and clinicians with gaps in their knowledge of the 'true' symptoms of menopause.

New software tool identifies genetic mutations that influence disease risk

HOUSTON-Researchers at The University of Texas MD Anderson Cancer Center and other institutions have applied a newly developed software tool to identify genetic mutations that contribute to a person's increased risk for developing common, complex diseases, such as cancer. The research is published in the May 2014 edition of the journal Nature Biotechnology.

Study links urbanization and future heat-related mortality

TEMPE, Ariz. – Phoenix stands at a parched crossroads. Global scale climate change is forecast to bring hotter summers and more extreme heat to the Valley, but regional urbanization also will impact temperatures experienced by residents.

So how should Phoenix grow knowing that such growth could cause temperatures to increase in the future and bring added health risks? Should the city deploy mitigating technologies to help fight summer's heat? Would adopting a low-growth strategy reduce the adverse health consequences of hot weather?

DNA-binding fluorescent dyes detect real-time cell toxicity during drug screening

New Rochelle, NY, May 30, 2014—High throughput screening of compounds in live cells is a powerful approach for discovering new drugs, but the potential for cell toxicity must be considered. A novel technique that uses DNA-binding fluorescent dyes to evaluate the cytotoxicity of an experimental compound in real-time during screening, saving time and resources, is described in ASSAY and Drug Development Technologies, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Study explains how green tea could reduce pancreatic cancer risk

LOS ANGELES – (May 30, 2014) – Green tea and its extracts have been widely touted as potential treatments for cancer, as well as several other diseases. But scientists have struggled to explain how the green tea and its extracts may work to reduce the risk of cancer or to slow the growth of cancer cells.

Moffitt Cancer Center instrumental in new clinical guidelines for cancer-related fatigue

TAMPA, Fla. (May 30, 2014) – Fatigue is a debilitating problem for cancer patients undergoing treatment; however, it also poses a huge detriment after treatment and can significantly affect quality of life. Approximately 30 percent of cancer patients endure persistent fatigue for several years after treatment, according to an American Society of Clinical Oncology Expert Panel co-chaired by Paul Jacobsen, Ph.D., associate center director of Population Sciences at Moffitt Cancer Center.

Study highlights side effects felt by BRCA mutation carriers after cancer risk-reducing procedure

PHILADELPHIA — The majority of women with cancer causing BRCA1 and BRCA2 mutations experience sexual dysfunction, menopausal symptoms, cognitive and stress issues, and poor sleep following prophylactic removal of their Fallopian tubes and ovaries - a procedure known as risk-reducing salpingo-oophorectomy (RRSO) - according to results of a new study from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania.